[go: up one dir, main page]

NO20062978L - Reduksjon av dermal arrdannelse - Google Patents

Reduksjon av dermal arrdannelse

Info

Publication number
NO20062978L
NO20062978L NO20062978A NO20062978A NO20062978L NO 20062978 L NO20062978 L NO 20062978L NO 20062978 A NO20062978 A NO 20062978A NO 20062978 A NO20062978 A NO 20062978A NO 20062978 L NO20062978 L NO 20062978L
Authority
NO
Norway
Prior art keywords
reduction
dermal scarring
scarring
dermal
p2iwafi
Prior art date
Application number
NO20062978A
Other languages
English (en)
Inventor
Danling Gu
Monica Zepeda
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO20062978L publication Critical patent/NO20062978L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåter og preparater for reduksjon eUer inhibering av dermal arrdarmelse ved ekspresjon av p2iWAFi/cipi ¿ g^ g^gg^ tilveiebringes.
NO20062978A 2003-11-24 2006-06-26 Reduksjon av dermal arrdannelse NO20062978L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52499303P 2003-11-24 2003-11-24
PCT/US2004/039633 WO2005051971A1 (en) 2003-11-24 2004-11-23 Reduction of dermal scarring

Publications (1)

Publication Number Publication Date
NO20062978L true NO20062978L (no) 2006-06-26

Family

ID=34632948

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062978A NO20062978L (no) 2003-11-24 2006-06-26 Reduksjon av dermal arrdannelse

Country Status (13)

Country Link
US (3) US7465442B2 (no)
EP (1) EP1692154A4 (no)
JP (2) JP4842139B2 (no)
KR (1) KR101167330B1 (no)
CN (2) CN100482674C (no)
AU (1) AU2004293474B2 (no)
BR (1) BRPI0416920A (no)
CA (1) CA2546287C (no)
IL (1) IL175603A (no)
NO (1) NO20062978L (no)
NZ (1) NZ546983A (no)
WO (1) WO2005051971A1 (no)
ZA (1) ZA200604147B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100482674C (zh) * 2003-11-24 2009-04-29 坎吉有限公司 皮肤瘢痕形成的减少
ES2751997T3 (es) 2008-01-14 2020-04-02 Conventus Orthopaedics Inc Aparato de reparación de fracturas
CN102405286A (zh) 2008-09-22 2012-04-04 阿克赛医药公司 减小大小的自递送RNAi化合物
US20110178520A1 (en) 2010-01-15 2011-07-21 Kyle Taylor Rotary-rigid orthopaedic rod
ES2733729T3 (es) 2010-01-20 2019-12-02 Conventus Orthopaedics Inc Aparato para el acceso a huesos y para la preparación de cavidades
WO2011112615A1 (en) 2010-03-08 2011-09-15 Krinke Todd A Apparatus and methods for securing a bone implant
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
KR20160110370A (ko) * 2013-12-04 2016-09-21 알엑스아이 파마슈티칼스 코포레이션 화학적으로 변형된 올리고뉴클레오티드를 사용한 상처 치유의 치료 방법
WO2015089357A2 (en) 2013-12-12 2015-06-18 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
US11311487B2 (en) 2016-04-14 2022-04-26 Trizell Ltd. Viral vector stabilization
WO2019010252A2 (en) 2017-07-04 2019-01-10 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4505266A (en) 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
AU8532691A (en) * 1990-08-01 1992-03-02 Chiron Ophthalmics Inc. Method for treating corneal endothelial wounds
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
DK0665886T3 (da) 1992-10-16 2003-10-06 Cold Spring Harbor Lab Omlejring af cyklinkomplekser og anvendelser, der er relateret dertil
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
EP0723402B1 (en) 1993-08-30 2010-08-18 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
CN1128049A (zh) 1994-03-18 1996-07-31 犹他大学研究基金会 多肿瘤抑制因子基因种系突变及检测该基因癌肿倾向性的方法
ES2233943T3 (es) 1994-05-24 2005-06-16 Baylor College Of Medicine Mimeticos de inhibidores de la sintesis de dna derivados de celulas senescentes.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
WO1996012506A1 (en) 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
WO1996019244A1 (en) 1994-12-22 1996-06-27 The University Of North Carolina At Chapel Hill DNA ENCODING A 20 Kd CDK6 INHIBITING PROTEIN
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
CA2227193A1 (en) 1995-07-17 1997-02-06 Xiaomei Jin P16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU1837197A (en) * 1996-01-26 1997-08-20 United States of America, represented by the Secretary, Department of Health and Human Services, The National Institutes of Health, The Hydroxylamine compositions for the prevention or retardation of cataracts
JP2000510449A (ja) 1996-04-10 2000-08-15 南カリフォルニア大学 増殖性硝子体網膜症に対する遺伝子治療
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
JPH11205102A (ja) 1998-01-13 1999-07-30 Mitsubishi Electric Corp 遅延同期回路
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
AU6919300A (en) * 1999-08-20 2001-03-19 University Of Pittsburgh Methods for in vivo gene delivery to sites of cartilage damage
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US6667173B2 (en) 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
CN100482674C (zh) * 2003-11-24 2009-04-29 坎吉有限公司 皮肤瘢痕形成的减少
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders

Also Published As

Publication number Publication date
CA2546287A1 (en) 2005-06-09
KR101167330B1 (ko) 2012-07-23
CN101507822A (zh) 2009-08-19
US20090142397A1 (en) 2009-06-04
IL175603A (en) 2011-02-28
KR20060127414A (ko) 2006-12-12
US20050271623A1 (en) 2005-12-08
US7465442B2 (en) 2008-12-16
JP4842139B2 (ja) 2011-12-21
CN1906205A (zh) 2007-01-31
AU2004293474A1 (en) 2005-06-09
CN100482674C (zh) 2009-04-29
IL175603A0 (en) 2006-09-05
CN101507822B (zh) 2012-06-06
WO2005051971A1 (en) 2005-06-09
US20110129534A1 (en) 2011-06-02
US8329671B2 (en) 2012-12-11
ZA200604147B (en) 2007-11-28
CA2546287C (en) 2014-04-22
AU2004293474B2 (en) 2010-12-23
BRPI0416920A (pt) 2007-01-23
JP2011207912A (ja) 2011-10-20
EP1692154A4 (en) 2009-07-08
EP1692154A1 (en) 2006-08-23
JP2007512377A (ja) 2007-05-17
NZ546983A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE256672T1 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
WO2006023651A3 (en) Extended treatment of multiple sclerosis
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
ATE368651T1 (de) Pyridazinon-derivate als gsk-3beta-hemmer
NO20070866L (no) Antivirale forbindelser.
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2006063048A3 (en) Ibudilast for treating neuropathic pain and associated syndromes
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
WO2004091572A3 (en) Cochleate compositions directed against expression of proteins
NO20062978L (no) Reduksjon av dermal arrdannelse
MXPA05002489A (es) Composiciones para el cuidado personal basadas en alcohol ramificado.
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
TW200508233A (en) Chk-1 inhibitors
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
DE60329326D1 (de) Tace inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
WO2006044378A3 (en) Rapid computational identification of targets

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application